Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 4Terminated 3Completed 3Active not recruiting 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Head & Neck 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Colorectal Neoplasms 492Pancreatic Neoplasms 387Carcinoma, Hepatocellular 261Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190Esophageal Neoplasms 157Neoplasms 139Carcinoma, Non-Small-Cell Lung 133Liver Neoplasms 129Neoplasm Metastasis 124Breast Neoplasms 102Cholangiocarcinoma 94Melanoma 85Ovarian Neoplasms 79Lung Neoplasms 72Squamous Cell Carcinoma of Head and Neck 57Carcinoma, Renal Cell 57Gastrointestinal Neoplasms 55Sarcoma 46Biliary Tract Neoplasms 39Prostatic Neoplasms 36Head and Neck Neoplasms 36Esophageal Squamous Cell Carcinoma 36Adenocarcinoma Of Esophagus 36Urinary Bladder Neoplasms 33Adenocarcinoma 33Uterine Cervical Neoplasms 31Triple Negative Breast Neoplasms 31Gastrointestinal Stromal Tumors 31

Interventions

pembrolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Adenoid Cystic × Gastrointestinal × Clear all
NCT05194072 2026-01-09

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Seagen Inc.

Phase 1 Terminated
250 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03422679 2024-01-16

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Cellestia Biotech AG

Phase 1/2 Terminated
79 enrolled 22 charts
BreastGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Carcinoma, Adenoid Cystic, Glomus Tumor, Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Osteosarcoma, Colorectal Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03680560 2020-03-31

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Cogent Biosciences, Inc.

Phase 1 Terminated
6 enrolled
BreastGastrointestinal

Breast Neoplasms, Carcinoma, Adenoid Cystic, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡